Research Programs
Product Development Pipeline
kt-2000 Next Generation PARP-inhibitors
PARP inhibitors are rapidly becoming standard-of-care treatment of many cancers including breast, ovarian and prostate cancer.
Our kt-2000 series is a patented class of highly potent, oral inhibitors of poly (ADP-ribose) polymerase (PARP).
Our lead candidates demonstrate potency comparable to FDA-approved PARP-inhibitors with potential differentiating factors and competitive advantages designed to improve treatment outcomes and patient quality of life.
kt-3000 Dual Action DDR-inhibitors
Cancer cells can develop resistant to treatment by up-regulating secondary DDR pathways.
kt-3000 drug candidates selectively inhibit secondary DDR pathways associated with treatment resistance and PARP
Preclinical data demonstrates on-target potency similar to FDA approved single-action agents
kt-4000 DNA Damaging DDR-inhibitors
kt-4000 drug candidates release a potent DNA-damaging agent, while also inhibiting DDR to selectively kill cancer cells